Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.68 [0.53, 0.87] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | crucial | - |
progression or deaths (PFS) | 0.59 [0.49, 0.72] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
objective responses (ORR) | 2.21 [1.58, 3.10] | | > 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
AE (any grade) | 0.18 [0.12, 0.27] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
AE (grade 3-4) | 0.19 [0.13, 0.29] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
AE leading to death (grade 5) | 1.24 [0.46, 3.38] | | < 1 | | 0% | 1 study (1/-) | 33.4 % | NA | not evaluable | | non important | - |
AE leading to treatment discontinuation (any grade) | 1.62 [0.82, 3.21] | | < 1 | | 0% | 1 study (1/-) | 8.2 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Colitis TRAE (grade 3-4) | 0.96 [0.02, 48.69] | | < 1 | | 0% | 1 study (1/-) | 50.7 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 0.48 [0.02, 14.38] | | < 1 | | 0% | 1 study (1/-) | 66.1 % | NA | not evaluable | | non important | - |
Hepatitis TRAE (grade 3-4) | 1.93 [0.06, 57.70] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 0.96 [0.02, 48.69] | | < 1 | | 0% | 1 study (1/-) | 50.7 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 0.96 [0.02, 48.69] | | < 1 | | 0% | 1 study (1/-) | 50.7 % | NA | not evaluable | | non important | - |
Increase AST TRAE (grade 3-4) | 3.87 [0.17, 86.12] | | < 1 | | 0% | 1 study (1/-) | 19.9 % | NA | not evaluable | | non important | - |
Increased ALT TRAE (grade 3-4) | 1.93 [0.06, 57.70] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
Maculopapular rash TRAE (grade 3-4) | 1.93 [0.06, 57.70] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
Nephritis TRAE (grade 3-4) | 0.96 [0.02, 48.69] | | < 1 | | 0% | 1 study (1/-) | 50.7 % | NA | not evaluable | | non important | - |
Peripheral neuropathy TRAE (grade 3-4) | 1.93 [0.06, 57.70] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 1.93 [0.06, 57.70] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 3.87 [0.17, 86.12] | | < 1 | | 0% | 1 study (1/-) | 19.9 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
hepatitis (Autoimmune) AE (grade 3-4) | 1.93 [0.06, 57.70] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
Acute kidney injury AE (grade 3-4) | 0.24 [0.01, 5.34] | | < 1 | | 0% | 1 study (1/-) | 81.4 % | NA | not evaluable | | non important | - |
Alopecia AE (grade 3-4) | 0.24 [0.01, 5.34] | | < 1 | | 0% | 1 study (1/-) | 81.4 % | NA | not evaluable | | non important | - |
Anaemia AE (grade 3-4) | 0.03 [0.01, 0.13] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Arthralgia AE (grade 3-4) | 0.48 [0.02, 14.38] | | < 1 | | 0% | 1 study (1/-) | 66.1 % | NA | not evaluable | | non important | - |
Asthenia AE (grade 3-4) | 0.48 [0.02, 14.38] | | < 1 | | 0% | 1 study (1/-) | 66.1 % | NA | not evaluable | | non important | - |
Back pain AE (grade 3-4) | 0.48 [0.02, 14.38] | | < 1 | | 0% | 1 study (1/-) | 66.1 % | NA | not evaluable | | non important | - |
Blood creatinine increased AE (grade 3-4) | 0.48 [0.02, 14.38] | | < 1 | | 0% | 1 study (1/-) | 66.1 % | NA | not evaluable | | non important | - |
Constipation AE (grade 3-4) | 0.96 [0.02, 48.69] | | < 1 | | 0% | 1 study (1/-) | 50.7 % | NA | not evaluable | | non important | - |
Decreased appetite AE (grade 3-4) | 0.96 [0.06, 15.46] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
Diarrhoea AE (grade 3-4) | 0.16 [0.02, 1.32] | | < 1 | | 0% | 1 study (1/-) | 95.5 % | NA | not evaluable | | non important | - |
Dyspnoea AE (grade 3-4) | 1.93 [0.17, 21.41] | | < 1 | | 0% | 1 study (1/-) | 29.7 % | NA | not evaluable | | non important | - |
Fatigue AE (grade 3-4) | 0.72 [0.16, 3.24] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
Febrile neutropenia AE (grade 3-4) | 0.06 [0.00, 1.03] | | < 1 | | 0% | 1 study (1/-) | 97.3 % | NA | not evaluable | | non important | - |
Hypertension AE (grade 3-4) | 0.24 [0.01, 5.34] | | < 1 | | 0% | 1 study (1/-) | 81.4 % | NA | not evaluable | | non important | - |
Increase AST AE (grade 3-4) | 4.87 [0.57, 41.91] | | < 1 | | 0% | 1 study (1/-) | 7.6 % | NA | not evaluable | | non important | - |
Increased ALT AE (grade 3-4) | 5.82 [0.29, 116.64] | | < 1 | | 0% | 1 study (1/-) | 12.7 % | NA | not evaluable | | non important | - |
Increased Lipase Level AE (grade 3-4) | 1.93 [0.06, 57.70] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
Leucopenia AE (grade 3-4) | 0.10 [0.01, 0.83] | | < 1 | | 0% | 1 study (1/-) | 98.3 % | NA | not evaluable | | non important | - |
myocarditis AE (grade 3-4) | 0.96 [0.02, 48.69] | | < 1 | | 0% | 1 study (1/-) | 50.7 % | NA | not evaluable | | non important | - |
Nausea AE (grade 3-4) | 0.12 [0.01, 2.26] | | < 1 | | 0% | 1 study (1/-) | 91.9 % | NA | not evaluable | | non important | - |
Neutropenia AE (grade 3-4) | 0.05 [0.01, 0.21] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Pancytopenia (AE grade 3-4) | 0.48 [0.02, 14.38] | | < 1 | | 0% | 1 study (1/-) | 66.1 % | NA | not evaluable | | non important | - |
Peripheral neuropathy AE (grade 3-4) | 0.96 [0.06, 15.46] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
Peripheral sensory neuropathy AE (grade 3-4) | 0.48 [0.02, 14.38] | | < 1 | | 0% | 1 study (1/-) | 66.1 % | NA | not evaluable | | non important | - |
Pneumonia AE (grade 3-4) | 0.77 [0.20, 2.88] | | < 1 | | 0% | 1 study (1/-) | 65.2 % | NA | not evaluable | | non important | - |
Pneumonitis AE (grade 3-4) | 1.93 [0.06, 57.70] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
Rash AE (grade 3-4) | 5.82 [0.29, 116.64] | | < 1 | | 0% | 1 study (1/-) | 12.7 % | NA | not evaluable | | non important | - |
Rash maculopapular AE (grade 3-4) | 1.93 [0.06, 57.70] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
Stomatitis AE (grade 3-4) | 0.48 [0.02, 14.38] | | < 1 | | 0% | 1 study (1/-) | 66.1 % | NA | not evaluable | | non important | - |
Thrombocytopenia AE (grade 3-4) | 0.02 [0.00, 0.30] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
Vomiting AE (grade 3-4) | 0.12 [0.01, 2.26] | | < 1 | | 0% | 1 study (1/-) | 91.9 % | NA | not evaluable | | non important | - |
Weight decreased AE (grade 3-4) | 1.93 [0.06, 57.70] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |